Meeting Program > Program Agenda


 

2011 Genitourinary Cancers Symposium
Program Agenda


Thursday, February 17, 2011

7:00 AM – 6:20 PM
Exhibit Hall Open

7:00 AM – 8:00 AM
Continental Breakfast Provided

8:00 AM – 9:45 AM
Welcome and General Session I: Emerging Trends in the Characterization and Treatment
Decisions in Newly Diagnosed Prostate Cancer

Chairs: Leonard G. Gomella, MD, FACS - Thomas Jefferson University
Alan Pollack, MD, PhD - University of Miami Miller School of Medicine
 

Decision Making Based on Predictors of Clinical Progression
Leonard G. Gomella, MD, FACS - Thomas Jefferson University
  Pathologic Assessment of Active Surveillance
Angelo DeMarzo, MD, PhD - James Buchanan Brady Urological Institute
  Molecular Characterization/Individualization of Prostate Cancer
Martin Gleave, MD, FRCSC, FACS - Vancouver General Hospital
  Abstract #1: Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels.
W. U. Shipley, D. Hunt, H. R. Lukka, P. Major, N. M. Heney, D. Grignon, M. Patel, J. P. Bahary, C. A. Lawton, and H. M. Sandler
  Abstract #2: Effect of dutasteride on prostate cancer progression and cancer diagnosis on rebiopsy in the REDEEM active surveillance study.
N. Fleshner, M. S. Lucia, K. Melich, I. M. Nandy, L. Black, and R. S. Rittmaster
  Q&A


9:45 AM – 10:15 AM
Break

10:15 AM – 11:45 AM
General Session II: Prostate Cancer Therapy for Recurrent Disease*

Chairs: Mack Roach, III, MD - University of California, San Francisco
Oliver Sartor, MD - Tulane Cancer Center
  Overview of Management of Radiation Failures in Prostate Cancer
Mack Roach, III, MD - University of California, San Francisco
  Case Study and Panel Discussion: Local Recurrences Following External Beam Radiotherapy: Cryotherapy, Surgery or Brachytherapy?
Panelists:
Richard Stock, MD - Mount Sinai Medical Center
Peter T. Scardino, MD - Memorial Sloan-Kettering Cancer Center
Jelle Barentsz, MD - University Medical Center Nijmegen
  Role of Traditional and Modern Hormone Therapy for Radiation Failures
Eric J. Small, MD - University of california, San Francisco
  Abstract #3: A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013.
L. Klotz, C. J. O'Callaghan, K. Ding, D. P. Dearnaley, C. S. Higano, E. M. Horwitz, S. Malone, S. L. Goldenberg, M. K. Gospodarowicz, and J. M. Crook
  Abstract #4: Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy.
H. I. Scher, C. Logothetis, A. Molina, O. B. Goodman, C. N. Sternberg, K. N. Chi, T. S. Kheoh, C. M. Haqq, K. Fizazi, and J. S. De Bono
  Case Study and Panel Discussion: Castration-resistant Prostate Cancer after Initial Chemotherapy
Panelists:
Oliver Sartor, MD - Tulane Cancer Center
Daniel P. Petrylak, MD - Columbia Presbyterian Medical Center
Michael J. Morris, MD - Memorial Sloan-Kettering Cancer Center
David I. Quinn, MD, PhD, FRACP - University of Southern California
Christopher Logothetis, MD - M.D. Anderson Cancer Center


11:45 AM – 1:00 PM
General Poster Session A: Prostate Cancer
Boxed Lunch Provided

1:00 PM – 2:50 PM
Oral Abstract Session A: Prostate Cancer
 

Chairs: Robert S. DiPaola, MD – The Cancer Institute of New Jersey
Christopher Evans, MD, FACS – University of California,  Davis
  Abstract #7: Prostate cancer incidence and disease-specific survival in men participating in the ERSPC with an initial PSA less than 3.0 ng/mL.
M. Bul, P. J. van Leeuwen, X. Zhu, F. H. Schröder, and M. J. Roobol
  Abstract #8: The impact of comorbidity on survival among men with localized prostate cancer.
G. L. Lu-Yao, D. Moore, W. Shih, Y. Lin, H. Li, and P. C. Albertsen
  Abstract #9: Correlation of radiotherapy with cause-specific and overall survival in clinically node-positive prostate cancer.
J. D. Tward and D. C. Shrieve
  Abstract #10: PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen-deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer (GETUG-AFU 15/0403).
G. Gravis, K. Fizazi, F. Joly, S. Oudard, F. Priou, I. Latorzeff, R. Delva, B. Esterni, M. Habibian, and M. Soulie
  Abstract #11: A phase II study of pomegranate extract for men with rising prostate-specific antigen following primary therapy.
M. A. Carducci, C. J. Paller, P. Wozniak, P. Sieber, R. Greengold, B. Stockton, B. Hertzman, R. Roper, H. Liker, and X. Ye
  Abstract #12: Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer.
N. D. Shore, J. W. Moul, E. D. Crawford, E. van der Meulen, T. K. Olesen, and B. E. Persson
  Discussion
Michael J. Morris, MD - Memorial Sloan-Kettering Cancer Center
  Abstract #13: Multiplex panel of metabolomic markers for early detection of prostate cancer.
S. K. Vareed, J. Siddiqui, V. Putluri, N. Putluri, T. M. Rajendiran, J. T. Wei, M. K. Terris, A. Chinnaiyan, G. Michailidis, and A. Sreekumar
  Abstract #14: Use of variation in sex steroid methyl transferases to predict efficacy of androgen-deprivation therapy (ADT) in advanced prostate cancer.
M. Kohli, D. W. Mahoney, H. S. Chai, D. W. Hillman, D. R. Rider, B. A. Costello, and J. R. Cerhan
  Abstract #15: Utilizing gleason pattern 5 to refine risk stratification for prostate cancer patients treated with dose-escalated radiotherapy and androgen-deprivation therapy.
A. Sabolch, F. Y. C. Feng, S. Daignault-Newton, S. Halverson, K. Blas, L. Phelps, K. B. Olson, H. M. Sandler, and D. A. Hamstra
  Discussion
Karen E. Knudsen, PhD - Thomas Jefferson University



2:50 PM – 3:20 PM
Break

3:20 PM – 4:50 PM
General Session III: Translational Science Session: New Targets for Prostate Cancer Therapy^

Chairs: Robert S. DiPaola, MD - The Cancer Institute of New Jersey
Jeffrey Schlom, PhD - National Cancer Institute
  Overview of Translational Aspects of Drug Development in Prostate Cancer
Robert S. DiPaola, MD - The Cancer Institute of New Jersey
  Immune Targeting in Prostate Cancer
Jeffrey Schlom, PhD - National Cancer Institute
  Aspects of the Androgen Receptor Pathway in Prostate Cancer
Karen E. Knudsen, PhD - Thomas Jefferson University Kimmel Cancer Center
  Abstract #5: Prostate cancer outcomes and polymorphism in LHRH and LH receptors and SHBG.
S. Liu, J. K. Pinski, and S. A. Ingles
  Abstract #6: Identification of gene copy number and whole-genome methylation changes associated with lethal metastatic castration-resistant prostate cancer (CRPC).
T. W. Friedlander, R. Roy, S. A. Tomlins, Y. Kobayashi, M. A. Rubin, K. J. Pienta, A. Chinnaiyan, E. J. Small, C. J. Ryan, and P. Paris
  e-Q&A


4:50 PM – 6:20 PM
Reception and General Poster Session B: Prostate Cancer
Wine and cheese provided
 
5:00 PM – 6:20 PM
Fellows Poster Walk: Prostate Cancer
(Ticket Required – Attendance Limited to Fellows, Residents, and Junior Faculty)

Leaders: Gary Hudes, MD - Fox Chase Cancer Center
Adam Kibel, MD - Washington University School of Medicine 


Friday, February 18, 2011

6:30 AM – 6:15 PM
Exhibit Hall Open

6:30 AM – 8:00 AM
Continental Breakfast Provided

7:00 AM – 7:50 AM
Best of Journals Session (Prostate Cancer)

Speakers: Daniel W. Lin, MD – University of Washington
David Raben, MD – University of Colorado Hospital
Elisabeth I. Heath, MD – Karmanos Cancer Center

8:00 AM – 9:45 AM
Welcome and General Session IV: Urothelial Carcinomas: Cases in Perioperative Chemotherapy*

Chairs: Arlene Siefker-Radtke, MD - M.D. Anderson Cancer Center
Seth Lerner, MD - Baylor College of Medicine
  Abstract #235: Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
C. Blick, P. Hall, T. Pwint, N. Munro, J. Crew, T. Powles, V. M. Macaulay, F. Al-Terkait, A. Protheroe, and J. D. Chester
  Abstract #236: Germline single-nucleotide polymorphisms (SNPs) associated with response of urothelial carcinoma (UC) to platinum-based therapy: The role of the host.
D. Gallagher, V. Joseph, I. R. Garcia-Grossman, J. A. Przybylo, J. C. Riches, I. Ostrovnaya, R. Hamilton, M. I. Milowsky, K. Offit, and D. F. Bajorin
 

Case Presentations and Panel Discussion
Panelists:
David Wood, MD - University of Michigan
Arlene Siefker-Radtke, MD - M.D. Anderson Cancer Center
Jason A. Efstathiou, MD, D.Phil - Massachusetts General Hospital
  Q&A


9:45 AM – 10:15 AM
Break

10:15 AM – 11:00 AM
Keynote Lecture

  Stem Cells and Tumorigenesis in Genitourinary Tumors
Carlos Cordon-Cardo, MD, PhD - Columbia University Medical Center


11:00 AM – 12:30 PM
General Session V: Penile, Urethral, and Testicular Cancers*

Chairs: Curtis A. Pettaway, MD - M.D. Anderson Cancer Center
Christopher Sweeney, MBBS - Dana-Farber Cancer Institute
  Introduction to GCT Post Chemo Session
Christopher Sweeney, MBBS - Dana-Farber Cancer Institute
  Abstract #224: Pathohistological findings in patients with nonseminomatous germ cell tumors (NSGCT) who undergo postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for small tumors.
D. J. K. P. Pfister, J. Busch, C. Winter, H. U. Schmelz, K. P. Dieckmann, P. Albers, M. Schrader, and A. Heidenreich
  Abstract #223: Late CT surveillance in non-seminoma germ cell tumors (NSGCT).
M. Singhera, B. Johnson, V. Harris, A. Horwich, D. P. Dearnaley, and R. A. Huddart
  Current Controversies in Residual Masses Management in Testicular Cancer
Lawrence Einhorn, MD - Indiana University Simon Cancer Center
  Overview of Issues in Penile Cancer
Curtis A. Pettaway, MD - M.D. Anderson Cancer Center
  Case Study and Panel Discussion
Panelists:
Simon Horenblas, MD, PhD - The Netherlands Cancer Institute
Juanita M. Crook, MD, FRCPC - Ontario Cancer Institute
Jean H. Hoffman-Censits, MD - Thomas Jefferson University Hospitals
  Q&A


12:30 PM – 1:45 PM
General Poster Session C: Penile, Urethral, Bladder and Testicular Cancers
Boxed Lunch Provided

12:40 PM – 1:45 PM
Fellows, Residents, and Junior Faculty Networking Luncheon
(Ticket Required – Attendance Limited to Fellows, Residents, and Junior Faculty)

1:45 PM – 3:15 PM
Oral Abstract Session B: Penile, Urethral, Bladder and Testicular Cancers

Chairs: Harry Herr, MD – Memorial Sloan-Kettering cancer Center
Anders Widmark, MD, PhD – Umea University Hospital
  Abstract #238: Defining “cisplatin ineligible” patients with metastatic bladder cancer.
M. D. Galsky, N. M. Hahn, J. E. Rosenberg, G. Sonpavde, W. K. Oh, R. Dreicer, N. J. Vogelzang, C. N. Sternberg, D. F. Bajorin, and J. Bellmunt
  Abstract #LBA239: A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer.
T. K. Choueiri, U. N. Vaishampayan, E. Y. Yu, D. I. Quinn, N. M. Hahn, T. E. Hutson, R. W. Ross, J. E. Rosenberg, S. J. Jacobus, and P. W. Kantoff
  Abstract #240: Multi-institutional quality-of-care initiative for non-metastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I.
A. Feifer, J. M. Taylor, M. Shouery, G. D. Steinberg, W. M. Stadler, M. Schoenberg, A. Zlotta, S. P. Lerner, D. F. Bajorin, and B. Bochner
  Abstract #241: Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC).
S. S. Sridhar, C. M. Canil, S. D. Mukherjee, E. Winquist, C. Elser, A. Eisen, M. N. Reaume, L. Zhang, and Y. J. Ko
  Abstract #242: Use of Immunocytology to predict bladder cancer presence in patients with asymptomatic hematuria.
E. K. Cha, L. A. Tirsar, S. F. Shariat, P. J. Christos, M. Mazumdar, J. Hennenlotter, C. Schwentner, C. Mian, M. Lodde, and B. J. Schmitz-Drager
  Abstract #243: Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in previously treated metastatic urothelial cancer.
Y. N. Wong, S. Litwin, E. R. Plimack, D. J. Vaughn, W. Song, S. M. Cohen, J. W. Lee, M. B. Dabrow, H. Tuttle, and G. R. Hudes
  Abstract #244: A phase II trial of neoadjuvant ABI-007, carboplatin, and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladder.
D. C. Smith, P. Grivas, S. Daignault, K. Hafez, D. P. Wood, C. T. Lee, J. E. Montie, A. Z. Weizer, J. Montgomery, and M. Hussain
  Abstract #255: Physician and patient factors influencing management recommendations in stage Ι testicular seminoma: A survey among radiation oncologists in the United States.
N. D. Arvold, P. J. Catalano, C. Sweeney, K. E. Hoffman, P. L. Nguyen, T. A. Balboni, S. D. Fossa, L. B. Travis, and C. Beard
  Abstract #256: Long-term survival and competing causes of death in men with stage I seminoma.
C. Beard, M. H. Chen, N. D. Arvold, P. L. Nguyen, A. K. Ng, and K. E. Hoffman

3:15 PM - 3:30 PM
Break

3:30 PM – 5:00 PM
General Session VI: Translational Science Session: Urothelial Carcinomas^

Chairs: Colin P.N. Dinney, MD - M.D. Anderson Cancer Center
Joaquim Bellmunt, MD - University Hospital del Mar
  Introduction
Colin P.N. Dinney, MD - M.D. Anderson Cancer Center
  Bladder Tumor Initiating Cells
Keith S. Chan, PhD - Baylor College of Medicine
  Review of Molecular Genetics and Gene Signatures of Bladder Cancer
David McConkey, PhD - M.D. Anderson Cancer Center
  Computational Biology in Urothelial Cancer
Joaquim Bellmunt, MD, PhD - University Hospital del Mar
  Mutational Analysis: New Targets, New Agents
Matthew I. Milowsky, MD - Memorial Sloan-Kettering Cancer Center
  Abstract #237: Alterations in genes regulating cell cycle and apoptosis in high-grade urothelial carcinoma.
H. Al-Ahmadie, G. Iyer, O. Lin, A. Gopalan, S. Fine, S. Tickoo, V. E. Reuter, D. F. Bajorin, M. I. Milowsky, and D. B. Solit
  e-Q&A


5:00 PM – 6:15 PM
Reception and General Poster Session C (continued): Penile, Urethral, Bladder and
Testicular Cancers
Wine and Cheese Provided

5:10 PM – 6:15 PM
Fellows Poster Walk: Penile, Urethral, Bladder and Testicular Cancers
(Ticket Required – Attendance Limited to Fellows, Residents, and Junior Faculty)

Leader: Joaquim Bellmunt, MD - University Hospital del Mar
Christopher Sweeney, MBBS – Dana-Farber Cancer  Institute

Saturday, February 19, 2011

6:30 AM – 8:00 AM
Continental Breakfast Provided

7:00 AM – 8:00 AM
General Poster Session D: Renal Cancer

7:00 AM – 7:50 AM
Best of Journals Session (Renal Cancer)

Speakers: Robert Uzzo, MD –Fox Chase Cancer Center
Hyung Lae Kim, MD – Cedars Sinai Medical Center
Primo N. Lara, Jr, MD – University of California, Davis

8:00 AM – 9:35 AM
Welcome and General Session VII: Renal Cancer*

Chairs: Paul Russo, MD - Memorial Sloan-Kettering Cancer Center
Anders Widmark, MD, PhD - Umea University Hospital
  Integration of Tyrosine Kinase Inhibitor Therapy with Surgery: Lymphadenectomy and Nephrectomy
Christopher G. Wood, MD - M.D. Anderson Cancer Center
  Abstract #299: Contrast enhanced CT (CE-CT) changes and nephrometry down-scoring of unresectable primary renal cell carcinoma (RCC) tumors in patients (Pts) treated with neoadjuvant sunitinib.
M. Salem, S. N. Shah, L. S. Wood, P. Elson, A. Medsinge, S. Campbell, and B. I. Rini
  Abstract #300: Postoperative complications from cytoreductive nephrectomy after neoadjuvant targeted therapy for metastatic renal cell carcinoma.
B. F. Chapin, S. E. Delacroix Jr., S. H. Culp, G. Gonzalez, and C. G. Wood
 

Case Study: Role of Surgical Resection in the Era of Targeted Therapies
Moderator: Christopher G. Wood, MD - M.D. Anderson Cancer Center
Panelists:
Tim Eisen, PhD, FRCP - University of Cambridge
Paul Russo, MD - Memorial Sloan-Kettering Cancer Center
Anders Widmark, MD, PhD - Umea University Hospital
  Management of Non-clear Cell Renal Carcinomas: From Chromophobe to
Sarcomatoid
Michael B. Atkins, MD - Beth Israel Deaconess
  Q&A


9:35 AM – 10:00 AM
Break

10:00 AM – 11:50 AM
Oral Abstract Session C: Renal Cancer

Chairs: Joaquim Bellmunt, MD – University Hospital del Mar
  Abstract #303: Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma.
C. F. Xu, H. A. Ball, N. Bing, C. N. Sternberg, Z. Xue, L. McCann, K. King, C. F. Spraggs, V. E. Mooser, and L. N. Pandite
  Abstract #304: Everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapies enrolled in the phase III RECORD-1 study.
R. A. Figlin, E. Calvo, R. J. Motzer, T. E. Hutson, S. Oudard, C. Porta, V. Grunwald, A. Ravaud, and E. Kpamegan
  Abstract #305: Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy.
D. Y. C. Heng, M. J. MacKenzie, U. N. Vaishampayan, J. J. Knox, G. A. Bjarnason, M. H. Tan, L. Wood, F. Donskov, B. I. Rini, and T. K. Choueiri
  Abstract #306: Phase I/II trial of concurrent sunitinib (SU) and image-guided radiotherapy (IGRT) followed by maintenance systemic therapy for patients with oligometastases.
J. Kao, J. A. Cesaretti, M. W. Sung, R. Stock, M. D. Galsky, S. Packer, and S. H. Chen
  Abstract #307: Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma (mRCC): Feasibility and clinical outcome.
S. Sadeghi, L. Albiges, L. S. Wood, S. L. Black, T. D. Gilligan, R. Dreicer, J. A. Garcia, B. J. Escudier, and B. I. Rini
  Discussion
David McDermott, MD - Beth Israel Deaconess Medical Center
  Abstract #LBA308: Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial.
R. J. Motzer, T. E. Hutson, M. R. Olsen, G. R. Hudes, J. M. Burke, W. J. Edenfield, G. Wilding, B. Martell, S. Hariharan, and R. A. Figlin
  Abstract #309: AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study.
B. I. Rini, C. Szczylik, N. M. Tannir, P. Koralewski, P. Tomczak, A. Deptala, K. Kracht, Y. N. Sun, M. Puhlmann, and B. Escudier
  Abstract #311: Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC).
A. M. Molina, D. R. Feldman, M. S. Ginsberg, P. Fischer, M. J. Trinos, S. Patil, and R. J. Motzer
  Discussion
Robert Dreicer, MD – The Cleveland Clinic


11:50 AM – 1:05 PM
General Poster Session D (continued): Renal Cancer
Boxed Lunch Provided

1:05 PM – 2:35 PM
General Session VIII: Translational Science Session: Renal Cancer^

Chairs: Gary R. Hudes, MD - Fox Chase Cancer Center
Michael B. Atkins, MD - Beth Israel Deaconess
  Rationale for Renal Biopsy and Molecular Characterization of the Small
Renal Mass
Victor Reuter, MD - Memorial Sloan-Kettering Cancer Center
  Genetic Basis of Kidney Cancer: Implications for Diagnosis and Management
W. Marston Linehan, MD - National Cancer Institute
  Prognostic and Predictive Factors in Renal Cell Carcinoma
Toni K. Choueiri, MD, MS - Dana-Farber Cancer Center
  Customizing Second Line Therapy: Integrating Clinical Prediction, Molecular Markers and Methods of Imaging
Bernard J. Escudier, MD - Institut Gustave Roussy
  Abstract #301: Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer.
T. Powles, S. Chowdhury, N. Avril, J. Bomanji, J. Shamash, N. Sarwar, A. Rockall, A. Sahdev, P. D. Nathan, and I. Kayani
  Abstract #302: Gene expression profile of circulating tumor cells (CTCs) in clear cell metastatic renal cell carcinoma (mRCC).
R. Iacovelli, C. Nicolazzo, A. Petracca, E. Risi, and E. Cortesi
  e-Q&A


2:35 PM
Adjourn

*This session will utilize an Audience Response System

^This session will utilize an e-Q&A system

Highlights
  • Educational Summaries are now available on the Program Agenda page
  • Full abstract texts are now available on the Program Agenda page
WebsiteFeedback